Sorafenib is the first targeted agent to treat metastatic kidney cancer
https://doi.org/10.17650/1726-9776-2015-1-73-78
Abstract
Sorafenib is the first registered new-generation targeted drug for the treatment of metastatic renal cell carcinoma (RCC). As of today, there have been as many as 7 medications used for targeted therapy for disseminated RCC. This has provided a possibility to choose a drug and raised a number questions also remaining relevant at this moment: Which drug treatment should be started? Which criterion should be used to evaluate the efficiency of treatment? Is there any optimal sequence of drugs?
The given review attempts to systemize the currently available data to answer the asked questions.
According to the results of recently completed trials, sorafenib ranks below other agents for first-line therapy for metastatic RCC in progression- free survival (PFS), which fails to translate into overall survival (OS) rates. In contrast, due to its properties, the multikinase inhibitor sorafenib ensures better OS rates, by achieving disease control in the larger proportion of cases (the number of objective replies + stabilization), and has an admissible toxicity profile; at the same time the probability of treatment discontinuation because of intolerability of the drug is not greater than 10 %. Thus, by taking into account of the possible sequence of targeted drugs, one should try to achieve the highest OS sooner than to use PFS as an efficiency criterion. The clinical findings have served as the basis for including sorafenib as an agent for first- and next-line therapy for RCC in the leading Russian (RUSSCO, Russian Society of Oncologists) and foreign (ESMO, NCCN) clinical guidelines.
About the Authors
V. B. Matveev
N.N. Blokhin Russian Cancer Research Center; 23, Kashirskoe Shosse, Moscow 115 478, Russia
Russian Federation
Russian Federation
V. A. Chernyaev
N.N. Blokhin Russian Cancer Research Center; 23, Kashirskoe Shosse, Moscow 115 478, Russia
Russian Federation
Russian Federation
References
1. http://www.fda.gov/NewsEvents/ Newsroom/PressAnnouncements/2005/ ucm108538.htm
2. Escudier B., Eisen T., Stadler W.M. et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 2009;27:3312–8.
3. Motzer R.J., Nosov D., Eisen T. et al. Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial. J Clin Oncol 2013;31:3791–9.
4. Motzer R.J., Porta C., Vogelzang N.J. et al. Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial. Lancet Oncol 2014;15:286–96.
5. Yuan J.L., Wang F.L., Yi X.M. et al. More than 10 years survival with sequential therapy in a patient with advanced renal cell carcinoma: a case report. Braz J Med Biol Res 2015;48(1):34–8.
6. Hutson T.E., Escudier B., Esteban E. et al. Randomized Phase III Trial of Temsirolimus Versus Sorafenib As Second-Line Therapy After Sunitinib in Patients With Metastatic Renal Cell Carcinoma. J Clin Oncol 32: 760–7.
7. Escudier B., Porta C., Bono P. et al. Randomized, controlled, double-blind, cross- over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study. J Clin Oncol 2014;32(14):1412–8.
8. Motzer R.J., Hutson T.E., Tomczak P. et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27(22):3584–90.
9. Motzer R.J., Hutson T.E, Cella D. et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med 2013;369(8):722–31.
10. Sternberg C.N., Hawkins R.E., Wagstaff J. et al. A randomised, double-lind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update. Eur J Cancer 2013;49(6): 1287–96.
11. Michel M.S., Vervenne W., de Santis M. et al. SWITCH: A randomized sequential open-label study to evaluate efficacy and safety of sorafenib (SO)/sunitinib (SU) versus SU/SO in the treatment of metastatic renal cell cancer (mRCC). J Clin Oncol 2014;32 (suppl 4; abstr 393).
Review
For citations:
Matveev V.B., Chernyaev V.A. Sorafenib is the first targeted agent to treat metastatic kidney cancer. Cancer Urology. 2015;11(1):73-78. (In Russ.) https://doi.org/10.17650/1726-9776-2015-1-73-78
Views:
3035
Email this article 